August 26, 2025

Regeneron’s cemdisiran shows promising results for myasthenia gravis – Investing.com

August 26, 2025

Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data – BioSpace

August 26, 2025

Late-stage trial boost for Argenx’s myasthenia gravis drug Vyvgart – European Pharmaceutical Review

August 26, 2025

Regeneron reports key phase 3 win in myasthenia gravis, gears up for FDA filing – Fierce Biotech

August 26, 2025

Regeneron to Submit Application for Cemdisiran in Myasthenia Gravis Following Positive Phase 3 NIMBLE Data

Regeneron’s cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.